Of moonshots, precision medicine, and progress in the management of cancer

As your sitemaster, let me be very clear about a couple of my most basic beliefs about prostate cancer and prostate cancer research. I want to do this because of all the recent media discussion about Vice President Byden’s “Moonshot” and the possible wonders of precision medicine. … READ MORE …

Planning out personalized therapy for metastatic prostate cancer

A new paper from researchers at the University of Santa Cruz and UCLA, just published in the journal Cell, has laid out the beginnings of a method to identify personalizable forms of therapy for men with metastatic forms of prostate cancer. … READ MORE …

The value in personalization of expectant management strategies

A recent and truly excellent review in Nature Reviews: Urology offers us a very thoughtful set of insights on the role of “expectant” and “conservative” management (i.e., active surveillance and watchful waiting) in the care of men with prostate cancer today. … READ MORE …

A small subgroup of patients with mCRPC responds to carboplatin + everolimus

There is an increasing level of evidence about our ability to identify small and carefully selected groups of patients with advanced disease who, despite the fact that they no longer respond to standard treatments, may respond well to other forms of therapy. … READ MORE …

What IS an “N-of-1” clinical trial?

As we come, slowly, closer and closer to truly individualized forms of medical practice, in which individual patients get treated individually based not just on “what works” for most men with (say) prostate cancer that has just progressed to the metastatic stage, clinical researchers are increasingly interested in so-called “N-of-1″ clinical trials. … READ MORE …

Just how helpful is personalized genomic analysis anyway?

Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …

“A plea for individualized prostate cancer screening”

For some years, Vickers, Lilja, and their associates have been arguing that baseline PSA level is able to predict long-term risk for prostate cancer, and now a new paper in European Urology seems to provide support for this argument and a practical clinical strategy for its application. … READ MORE …